Simulating Clinical Trials Using The FACTS Software Package

Date: 09-Jul-14 to 09-Jul-14
Location: Holiday Inn Bloomsbury / London / United Kingdom
Category: Science Conferences & Trade Fairs World & Regional

Join SMi's Simulating Clinical Trials Using the FACTS Software Package event on the 9 July in London, to hear how simulation of clinical trials is used in the trial design process and how it benefits.

Medical simulation is no longer an educational afterthought – it's a clinical learning necessity. Simulation adds considerable advantages to the clinical trial design process – using previous research data to its full potential, clarifying communication on the consequences of trial design options and allowing statisticians to consider and evaluate more complex trial designs.

The purpose of this masterclass hosted by Tessella is twofold, firstly to introduce the art of simulating clinical trials, and illustrating the many advantages of doing it. Secondly simulation will be demonstrated using the FACTS software (as this will allow us to specify and run simulations very quickly and visibly) and thus the workshop will show some of the capabilities of the FACTS software and how it can be used in trial design.

Why you should attend:
The workshop will help delegates understand how simulation of clinical trials is used in the trial design process and the benefits it brings – such as better understanding of operating characteristics, and allowing more complex designs that tackle contemporary problems of comparative effectiveness, efficacy/safety trade-off and subpopulation selection.

Price:
Standard Rate: £599

Visitors

Academic research manager
analyst
Associate Director
Associate Director Biostatistics
Associate Director of Clinical Pharmacology

Exhibitors

Academic research manager
analyst
Associate Director
Associate Director Biostatistics
Associate Director of Clinical Pharmacology

Go to event website

EIN News provides powerful, real-time media monitoring, news aggregation & syndication services. Read the latest news about this topic. See: